Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 29.80
Bid: 29.00
Ask: 30.70
Change: -0.90 (-2.93%)
Spread: 1.70 (5.862%)
Open: 28.80
High: 29.80
Low: 28.80
Prev. Close: 30.70
EKF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DiaSpect Tm McKesson US distribution agreement

9 Aug 2018 07:00

RNS Number : 2695X
EKF Diagnostics Holdings PLC
09 August 2018
 

 

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).

 

EKF Diagnostics Holdings plc

("EKF", the "Company")

 

DiaSpect Tm US distribution agreement with McKesson

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that it has signed a private label distribution agreement with McKesson Medical-Surgical Inc., an affiliate of McKesson Corporation - the Fortune Global 500 healthcare distribution specialist and one of the largest companies in the US by revenue - for the Company's hand-held reagent-free hemoglobin analyzer, the DiaSpect Tm.

 

The DiaSpect Tm is the world's fastest hemoglobin analyzer and will be branded in the US by McKesson under its own branded line, as the McKesson Consult® Hb analyzer.

 

The agreement follows US Food and Drug Administration 510(k) clearance and CLIA waiver by statute for the DiaSpect Tm in April 2018, approving the product for use in point of care and Certificate of Waiver settings. Sales of the McKesson Consult® Hb analyzer are expected following full launch in the autumn, 2018.

 

For more information on the DiaSpect Tm see: www.ekfdiagnostics.com/diaspect.html 

 

Commenting, Julian Baines, CEO of EKF, said:  

"As I said in April the US market is a key target for the DiaSpect Tm, which gives physicians access to an easy to use, accurate and portable hemoglobin measurement system able to deliver laboratory quality results at the point of care within seconds." 

 

"This agreement with McKesson allows us to offer this innovative technology to physicians and childcare specialists across the US through the market's leading and most established healthcare distribution player. We expect that this partnership will ultimately deliver significant value to shareholders."

 

 

Enquiries:

 

EKF Diagnostics Holdings plc 

www.ekfdiagnostics.com

Christopher Mills, Non-Executive Chairman

Tel: 029 2071 0570

Julian Baines, CEO 

Richard Evans, FD & COO

N+1 Singer (Nomad & Broker)

Tel: 020 7496 3000

Aubrey Powell / Shaun Dobson

Walbrook PR Limited

Tel: 020 7933 8780 or ekf@walbrookpr.com

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303

 

About McKesson Medical-Surgical mms.mckesson.com

McKesson Medical-Surgical Inc. is an affiliate of the McKesson Corporation. McKesson Corporation, currently ranked 6th on the FORTUNE 500, is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. McKesson Medical-Surgical works with health systems, physician offices, extended care providers, in-home patients, labs, payers and others across the spectrum of care to build healthier organizations that deliver better care to patients in every setting. McKesson Medical-Surgical helps its customers improve their financial, operational, and clinical performance with solutions that include pharmaceutical and medical-surgical supply management, healthcare information technology, and business and clinical services.

About EKF Diagnostics Holdings plc www.ekfdiagnostics.com

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGRDDGDIRBGBGII
Date   Source Headline
13th Jun 20227:00 amRNSUpdate on strong cash position
9th Jun 20227:00 amRNSLaunch of EKF Link
23rd May 20227:00 amRNSCancellation of Treasury Shares and TVR
18th May 20221:25 pmRNSResult of AGM
18th May 20227:00 amRNSAGM Statement
3rd May 20227:00 amRNSPDMR/Director Dealings & Holding(s) in Company
25th Apr 20227:00 amRNSPosting of Annual Report & Accounts &Notice of AGM
11th Apr 20227:00 amRNSPurchase of Own Shares & Buyback Prog. Completion
8th Apr 20227:00 amRNSPurchase of Own Shares
7th Apr 20227:00 amRNSPurchase of Own Shares
6th Apr 20227:00 amRNSPurchase of Own Shares
5th Apr 20227:00 amRNSPurchase of Own Shares
4th Apr 20227:00 amRNSPurchase of Own Shares
1st Apr 20227:00 amRNSPurchase of Own Shares
31st Mar 20227:00 amRNSPurchase of Own Shares
30th Mar 20227:00 amRNSPurchase of Own Shares
29th Mar 20227:01 amRNSShare Buyback Programme
29th Mar 20227:00 amRNSFinal Results
25th Mar 20224:40 pmRNSSecond Price Monitoring Extn
25th Mar 20224:35 pmRNSPrice Monitoring Extension
18th Mar 20225:13 pmRNSHolding(s) in Company
7th Mar 20227:00 amRNSFurther Investment in Verici Dx plc
3rd Mar 20224:41 pmRNSSecond Price Monitoring Extn
3rd Mar 20224:36 pmRNSPrice Monitoring Extension
3rd Mar 20227:00 amRNSNotice of Results
31st Jan 20227:00 amRNSNon-executive Directorate Change
25th Jan 20227:00 amRNSTrading update
18th Jan 20227:01 amRNSStrategic partnership agreement with Yourgene
23rd Nov 20217:00 amRNSDirectorate Change
8th Nov 20211:01 pmRNSDirector/PDMR Shareholding
25th Oct 20217:00 amRNSDividend confirmation
12th Oct 20217:00 amRNSCompletion of ADL Health Acquisition
5th Oct 20213:00 pmRNSPDMR/ PCA Dealings
5th Oct 20213:00 pmRNSHolding(s) in Company
28th Sep 20217:00 amRNSAcquisition of Advanced Diagnostic Laboratory LLC
14th Sep 20217:00 amRNSHalf-year Report
25th Aug 20217:00 amRNSNotice of Results
21st Jul 20217:00 amRNSTrading Update
16th Jun 20217:00 amRNSChange of Adviser
7th Jun 202110:10 amRNSInvestor Presentations
26th May 20215:48 pmRNSTrellus Health plc: Successful Restricted Offer
20th May 20214:31 pmRNSTrellus Health plc: Confirmation of Issue Price
19th May 202112:58 pmRNSResult of AGM
19th May 20217:01 amRNSBoard Changes and Executive Performance Bonus
19th May 20217:00 amRNSAGM Statement
18th May 20217:00 amRNSTrellus Health plc: Intention to Float - AIM
5th May 202111:14 amRNSNotice of Change of AGM Venue and Dividend Update
30th Apr 20213:52 pmRNSDirector/PDMR Shareholding
23rd Apr 20217:00 amRNSPosting of Annual Report &Accounts & Notice of AGM
22nd Apr 20217:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.